Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018–2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin
Abstract
Low vaccine effectiveness against A(H3N2) influenza in seasons with little antigenic drift has been attributed to substitutions in hemagglutinin (HA) acquired during vaccine virus propagation in eggs. Clinical trials comparing recombinant HA vaccine (rHA) and cell-derived inactivated influenza vaccine (IIV) to egg-derived IIVs provide opportunities to assess how egg-adaptive substitutions influence HA immunogenicity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 08, 2020
- Source ID
- 10.1093/cid/ciaa1352
Entities
People
- Ana Elizabeth Markelz
- Anuradha Ganesan
- Bruce Mcclenathan
- Carol D Weiss
- Casey Geaney
- Christian L. Coles
- Christina Schofield
- Christina Spooner
- David Hrncir
- Esmeralda Alvarado-facundo
- Gregory C Utz
- Katrin Mende
- Limone Collins
- Maryna Eichelberger
- Min Levine
- Rhonda E. Colombo
- Russell Vassell
- Ryan C. Maves
- Srihari Seshadri
- Stephanie A Richard
- Tahaniyat Lalani
- Timothy H. Burgess
- Tyler E Warkentien
- Wei Wang
Organizations
- Centers for Disease Control and Prevention
- Defense Health Agency
- Food and Drug Administration
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Madigan Army Medical Center
- Naval Medical Center Portsmouth
- Naval Medical Center San Diego
- San Antonio Military Medical Center
- Uniformed Services University of the Health Sciences
- United States Department of Defense
- Walter Reed National Military Medical Center